Management Changes

Cambridge, UK, 10 July 2024 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces certain management team changes.

• Tim Mitchell, co-founder and Chief Executive Officer (CEO), will, after twenty years with the Company, transition to the part-time role of Chief Operating Officer (COO). Dr. Mitchell will continue to serve on Sareum's Board of Directors (the "Board").
• Stephen Parker, currently Non-Executive Chairman, will assume the position of Executive Chairman on the Board. The Board currently intends to seek to appoint a new CEO, at the appropriate time, as the Company and its future strategy develops.

Additionally, Mr. Clive Birch has been appointed as Senior Independent Director.

Dr. Stephen Parker, Executive Chairman at Sareum, commented: "I'm really excited to be stepping into the position of Executive Chairman at Sareum at this critical time in the Company's history. Tim's decision to transition to the part-time role of COO comes at a time when we have achieved an important milestone of positive data from the Phase 1 trial of our lead product, SDC-1801. I would like to acknowledge the immense contribution Tim has made since founding the company twenty years ago. I wish him well as he takes up his new role at Sareum and I'm very pleased that we will continue to benefit from his expertise and experience."

• Tim Mitchell, Chief Operating Officer of Sareum added: "After many years as CEO, I am looking forward to transitioning into the role of Chief Operating Officer. I will continue to support Sareum's mission and work closely with Stephen and the Board as we advance the development of our pipeline. The positive data from the Phase 1 clinical trial of SDC-1801 highlights the potential of our lead product and sets a solid foundation for the future."